The SLE and LN market is projected to grow from $2.4 billion in 2024 to $5.9 billion by 2034 (9.6% CAGR), driven by 10 late-stage pipeline drugs offering improved safety and efficacy over current generic treatments. However, growth faces headwinds from biosimilar competition and high treatment costs limiting adoption rates.

The interstitial lung disease market is projected to grow at a CAGR of 8.7% from 2026-2036, driven by emerging therapies and pipeline candidates. The market was valued at USD 6 billion in 2025 across seven major markets, with the US accounting for 83% of the market. Key developments include FDA approval of nerandomilast (JASCAYD) for progressive pulmonary fibrosis and multiple late-stage candidates addressing immune dysregulation and fibrotic signaling.

The severe asthma drug development pipeline shows strong momentum with 30+ pharmaceutical companies actively developing 35+ pipeline therapies across various clinical stages. Key players including AstraZeneca, Generate Biomedicines, GSK, and others are advancing promising candidates targeting thymic stromal lymphopoietin inhibitors and interleukin pathways. Recent approvals and positive trial results, including GSK's Exdensur and Upstream Bio's verekitug, demonstrate progress in addressing this unmet medical need.

Sanofi reported positive Phase 2 data for lunsekimig, its bispecific antibody targeting TSLP and IL-13. The drug met primary endpoints in asthma and nasal polyp studies with significant improvements in exacerbations and polyp size. However, an atopic dermatitis trial missed its primary endpoint, though secondary measures showed some clinical activity. The drug demonstrated a favorable safety profile across all studies.

President Trump signed an executive order imposing 100% tariffs on imported pharmaceuticals, with 13 drug companies already exempt through Most Favored Nation (MFN) pricing agreements. Companies that signed deals and committed to U.S. manufacturing face 0% tariffs through 2029, while non-signatories face the full 100% levy starting July 31. The tariff threat has triggered over $150 billion in domestic manufacturing investments from deal-signing companies.

The Trump administration is preparing to announce 100% tariffs on pharmaceutical companies that haven't secured pricing deals with the White House, potentially as soon as Thursday. The tariffs stem from a Section 232 investigation citing national security grounds. Major drugmakers including Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk, and Johnson & Johnson have already secured three-year reprieves by agreeing to most-favored-nation pricing. The tariff threat is part of a broader pricing strategy that includes the TrumpRx.gov platform for comparing discounted drug prices.

SCYNEXIS announced the completion of its acquisition of PXL-770 (now SCY-770), a novel AMPK activator for treating ADPKD, the leading genetic cause of end-stage renal failure. Under the deal, SCYNEXIS will pay $8 million upfront with up to $188 million in potential milestone payments. The company plans to initiate a Phase 2 proof-of-concept study in Q4 2026 with early efficacy readout expected in H2 2027. SCY-770 has received FDA Orphan Drug Designation.

Sitryx Therapeutics, a clinical-stage biopharmaceutical company developing oral therapies for autoimmune and inflammatory diseases, announced its participation in four upcoming investor conferences in April 2026, including Wells Fargo Spring Virtual Private Biopharma Symposium, Needham & Company Healthcare Conference, H.C. Wainwright Inflammatory Skin Disease Conference, and Piper Sandler Spring Biopharma Symposium.

Amgen and GSK are joining TrumpRx.gov to offer significant prescription drug discounts. Amgen will provide up to 80% discounts on medications like Amjevita, while GSK will offer discounts ranging from 10-55% on drugs including Incruse. This expands TrumpRx's discounted medication offerings to 54 drugs from five pharmaceutical companies. The move reflects pressure from Trump administration policies on drug pricing through most-favored-nation (MFN) pricing agreements.

The 20th annual BIO-Europe Spring conference will take place in Lisbon, Portugal from March 23-25, 2026, attracting over 3,700 attendees from 2,000+ companies. The event expects over 20,000 one-to-one meetings and will feature key sessions on therapeutic landscapes, dealmaking strategies, and a startup pitch competition, with virtual partnering extending through April 1.

The FDA expanded approval for GSK's Arexvy RSV vaccine to include adults aged 18-49 at higher risk of severe RSV disease, previously limited to those 60 and older. The expansion addresses an unmet medical need among younger adults with chronic health conditions. Arexvy sales reached 198 million pounds in Q4 (up 25%), with Phase 3b trial data showing non-inferior immune response in younger adults compared to older populations.

The herpes zoster (shingles) market is experiencing steady growth driven by rising global incidence among aging populations and increased awareness of disease complications. The market is expected to expand significantly through 2036, fueled by vaccine adoption and the launch of emerging vaccines like Amezosvatein (CRV-101) and JCXH-105. SHINGRIX remains the current standard, while new candidates in Phase II trials are anticipated to reshape the market landscape.